Sanofi Price to Book Ratio 2010-2024 | SNY

Historical price to book ratio values for Sanofi (SNY) over the last 10 years. The current price to book ratio for Sanofi as of November 20, 2024 is 1.55.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Sanofi Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-11-19 48.00 inf
2024-09-30 57.63 0.00
2024-06-30 48.52 $31.04 1.56
2024-03-31 46.65 0.00
2023-12-31 47.73 $31.81 1.50
2023-09-30 51.49 0.00
2023-06-30 51.74 $31.50 1.64
2023-03-31 50.34 0.00
2022-12-31 44.80 $31.40 1.43
2022-03-31 45.96 0.00
2021-09-30 43.16 0.00
2021-03-31 42.66 0.00
2020-09-30 43.27 0.00
2020-03-31 36.39 0.00
2019-09-30 38.56 0.00
2019-03-31 35.37 0.00
2018-03-31 30.56 0.00
2017-12-31 32.79 $26.26 1.25
2017-09-30 37.97 0.00
2017-06-30 36.53 $25.22 1.45
2017-03-31 33.37 0.00
2016-12-31 29.83 $24.72 1.21
2016-09-30 28.17 0.00
2016-06-30 30.87 $23.85 1.29
2016-03-31 28.41 0.00
2015-09-30 33.58 0.00
2015-06-30 35.04 $23.95 1.46
2014-06-30 36.43 0.00
2013-06-30 34.07 0.00
2022-06-30 46.28 0.00
2012-06-30 24.14 0.00
2012-03-31 23.66 0.00
2011-12-31 22.31 0.00
2011-09-30 20.02 0.00
2011-06-30 24.52 0.00
2011-03-31 20.78 0.00
2010-12-31 19.02 0.00
2010-09-30 19.62 0.00
2010-06-30 17.74 0.00
2010-03-31 21.27 0.00
2009-12-31 22.35 0.00
2009-09-30 21.03 0.00
2009-06-30 16.79 0.00
2009-03-31 15.07 0.00
2022-09-30 35.17 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $121.816B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Innoviva (INVA) United States $1.195B 9.94